Education
About Us
Working with TipRanks
Follow Us
PSCH - ETF AI Analysis
Top Page
Invesco S&P SmallCap Health Care ETF (PSCH)
Rating:67Neutral
Price Target:―
Positive Factors
Strong Top Holdings
Several top holdings, such as Corcept Therapeutics and Protagonist Therapeutics, have delivered strong year-to-date gains, supporting the fund’s overall performance.
Focused Sector Exposure
The ETF’s heavy allocation to the health care sector provides targeted exposure to a resilient and innovative industry.
Low Expense Ratio
The fund’s expense ratio is relatively low, making it a cost-effective choice for investors seeking small-cap health care exposure.
Negative Factors
High Sector Concentration
With over 94% of the fund allocated to health care, it is highly sensitive to sector-specific risks.
Weak Overall Performance
The ETF has struggled year-to-date, reflecting challenges in the small-cap health care space.
Limited Geographic Diversification
The fund is almost entirely focused on U.S. companies, leaving investors exposed to domestic market risks.
PSCH vs. SPDR S&P 500 ETF (SPY)
AUM150.95M
RegionNorth America
Expense Ratio0.29%
Beta0.78
IssuerInvesco
Inception DateApr 07, 2010
Dividend Yield0.08%
Asset ClassEquity
Index TrackedS&P SmallCap 600 Capped Health Care Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume9,535
30 Day Avg. Volume11,557
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
56.16Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering76
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PSCH Summary
The Invesco S&P SmallCap Health Care ETF (PSCH) is an investment fund that focuses on small-cap companies in the U.S. health care sector. It tracks the S&P SmallCap 600 Capped Health Care Index, which includes businesses in areas like pharmaceuticals, biotechnology, medical devices, and health care services. Some of its top holdings include Corcept Therapeutics and Teleflex. Investors might consider PSCH for its potential growth, as smaller companies in health care often drive innovation and breakthroughs. However, it’s important to note that this ETF is heavily focused on health care, so its performance can be impacted by changes in the sector or broader market trends.
How much will it cost me?The Invesco S&P SmallCap Health Care ETF (PSCH) has an expense ratio of 0.29%, meaning you’ll pay $2.90 per year for every $1,000 invested. This cost is slightly higher than average because the ETF focuses on a niche sector and tracks small-cap health care companies, which require more active management compared to broad-market passive ETFs.
What would affect this ETF?The Invesco S&P SmallCap Health Care ETF (PSCH) could benefit from advancements in biotechnology, pharmaceuticals, and medical devices, as small-cap companies often drive innovation in the health care sector. However, it may face challenges from rising interest rates, which can increase borrowing costs for smaller companies, and regulatory changes in the U.S. health care industry that could impact profitability. The ETF’s focus on U.S. small-cap health care stocks makes it sensitive to domestic economic conditions and sector-specific trends.
PSCH Top 10 Holdings
The Invesco S&P SmallCap Health Care ETF (PSCH) leans heavily into the U.S. health care sector, with a focus on small-cap innovators in biotechnology, pharmaceuticals, and medical devices. Arrowhead Pharmaceuticals and Krystal Biotech are rising stars, buoyed by strong clinical developments and expansion strategies. Meanwhile, Glaukos and Teleflex are lagging, held back by profitability concerns and valuation challenges. This fund’s concentrated exposure to health care means it’s riding the wave of innovation but remains vulnerable to sector-specific headwinds, making it a dynamic yet potentially volatile choice for investors seeking growth.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | 4.82% | $7.25M | $8.83B | 251.54% | 57 Neutral | |
| Krystal Biotech | 3.64% | $5.48M | $7.22B | 62.77% | 80 Outperform | |
| Glaukos | 3.50% | $5.27M | $6.56B | -27.07% | 61 Neutral | |
| PTC Therapeutics | 3.36% | $5.06M | $6.17B | 74.90% | 72 Outperform | |
| Radnet | 2.93% | $4.41M | $6.06B | 13.96% | 63 Neutral | |
| Merit Medical Systems | 2.76% | $4.16M | $5.52B | -3.10% | 68 Neutral | |
| Teleflex | 2.69% | $4.05M | $4.86B | -37.00% | 68 Neutral | |
| Alkermes | 2.64% | $3.98M | $4.89B | 5.41% | 80 Outperform | |
| Protagonist Therapeutics | 2.54% | $3.83M | $5.01B | 119.06% | 68 Neutral | |
| TransMedics Group | 2.53% | $3.81M | $4.70B | 99.93% | 77 Outperform |
PSCH Technical Analysis
Positive
―
Price Trends
44.28
Positive
42.89
Positive
41.50
Positive
Market Momentum
0.15
Positive
53.41
Neutral
70.93
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PSCH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 45.49, equal to the 50-day MA of 44.28, and equal to the 200-day MA of 41.50, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 53.41 is Neutral, neither overbought nor oversold. The STOCH value of 70.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PSCH.
PSCH Peer Comparison
Comparison Results
Performance Comparison
PSCH
Invesco S&P SmallCap Health Care ETF
45.42
0.73
1.63%
FXH
First Trust Health Care AlphaDEX Fund
―
―
―
IHE
iShares U.S. Pharmaceuticals ETF
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
PINK
Simplify Health Care ETF
―
―
―
PTH
Invesco DWA Healthcare Momentum ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents